Clinical Trials Logo

Clopidogrel, Poor Metabolism of clinical trials

View clinical trials related to Clopidogrel, Poor Metabolism of.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04734028 Completed - Clinical trials for Coronary Artery Disease

PTRG-DES Consortium

PTRG
Start date: July 9, 2003
Phase:
Study type: Observational

The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

NCT ID: NCT03188705 Completed - Clinical trials for Coronary Artery Disease

CES1 Carriers in the PAPI Study

Start date: October 14, 2019
Phase: Phase 4
Study type: Interventional

This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396). The purpose of this investigation is to assess the impact of genetic variation in the carboxylesterase 1 (CES1) on response to clopidogrel as well as dual antiplatelet therapy (i.e. clopidogrel and aspirin), as assessed by ex vivo platelet aggregometry, in healthy Amish individuals. The investigators hypothesize that participants who carry alleles that modify the activity or expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet therapy.

NCT ID: NCT03174990 Completed - Clinical trials for Peripheral Arterial Disease

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

Start date: August 31, 2010
Phase: N/A
Study type: Observational

This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in patients with peripheral arterial disease (PAD) currently remain unknown.